{"id":607,"date":"2026-03-09T15:36:00","date_gmt":"2026-03-09T15:36:00","guid":{"rendered":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/?page_id=607"},"modified":"2026-03-09T16:53:53","modified_gmt":"2026-03-09T16:53:53","slug":"evoke-evoke","status":"publish","type":"page","link":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/evoke-evoke\/","title":{"rendered":"EVOKE\/EVOKE+"},"content":{"rendered":"\n
<\/div>
<\/div><\/div>
\n

EVOKE and EVOKE Plus: Two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease<\/h2>\n<\/div><\/div><\/div><\/div><\/div>\n\n\n\n
\n
\"EVOKE<\/figure>
\n

Project Details<\/strong><\/p>\n\n\n\n

Start Date
August 2021<\/strong><\/p>\n\n\n\n

Status
Closed to Recruitment<\/strong><\/p>\n\n\n\n

Principal Investigator
Dr Tom Russ<\/a><\/p>\n\n\n\n

NDN Study Lead
Jessica Crossan<\/a><\/p>\n\n\n\n

Main Research Site
Western General Hospital<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

This clinical trial looks to see if the oral version of the medication semaglutide<\/strong> can help treat Alzheimer\u2019s disease. <\/strong>The EVOKE and EVOKE Plus trials are similar, but are considered separate studies as people who also have cerebral vascular changes (heart conditions) will take part in the EVOKE Plus trial, instead.<\/p>\n\n\n\n

What Happens In This Study?<\/strong><\/p>\n\n\n\n

You will either be given a medicine called semaglutide<\/strong> or a placebo<\/strong> (a dummy pill that looks like the medicine but has no active ingredients). Neither you, nor the research team, will know which group you are in.<\/p>\n\n\n\n

Can I Join This Study?<\/strong><\/p>\n\n\n\n

To take part in this medical trial, you must meet these 8 requirements<\/strong>:<\/p>\n\n\n\n

    \n
  1. Your Diagnosis:<\/strong> A doctor must have confirmed that you have MCI or mild dementia of the Alzheimer\u2019s type<\/strong>.<\/li>\n\n\n\n
  2. Your Age:<\/strong> You are between 55 and 85 years old<\/strong>.<\/li>\n\n\n\n
  3. Your Symptoms:<\/strong> Your symptoms should be mild or moderate<\/strong>. A doctor will be able to assess your symptom severity.<\/li>\n\n\n\n
  4. Your Current Medicine:<\/strong> If you are taking Alzheimer\u2019s disease medication, you must have been taking this for at least 3 months,<\/strong> without making any big changes to it.<\/li>\n\n\n\n
  5. Your Study Partner:<\/strong> You must have a reliable friend of family member<\/strong> who knows you well and you see regularly, who can also take part to provide us with information on how you are doing.<\/li>\n\n\n\n
  6. Your Permission:<\/strong> You must be able to understand what happens in the study and sign a form (called informed consent<\/strong>) to say you agree to join.<\/li>\n\n\n\n
  7. Your Time:<\/strong> You must do your best to attend all your study visits, and follow the rules of the study until it ends.<\/li>\n\n\n\n
  8. Taking the Medicine:<\/strong> You must be willing and able to swallow the trial medication.<\/li>\n<\/ol>\n\n\n\n

    Study Length<\/strong>: 104 weeks (2 years), with an optional extension of 52 weeks (1 year)<\/p>\n\n\n\n

    Number of appointments<\/strong>: 13 visits, with an optional extension of 5 visits<\/p>\n\n\n\n

    More information on the trial can be found on the Novo Nordisk website<\/a>.<\/p>\n<\/div><\/div>\n\n\n\n